Search alternatives:
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
point decrease » point increase (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
Showing 1 - 20 results of 7,904 for search '(( significant treatment decrease ) OR ( significant ((main decrease) OR (point decrease)) ))', query time: 0.56s Refine Results
  1. 1
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
    Save to List
    Saved in:
  3. 3
    Cephalometric measurement points.

    Cephalometric measurement points. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    <i>Elsholtzia ciliata</i> extract (ECE) treatment decreases coronavirus-induced plaque formation.

    <i>Elsholtzia ciliata</i> extract (ECE) treatment decreases coronavirus-induced plaque formation. by Siyun Lee (17087351)

    Published 2025
    “…Cells were overlayed 0.3% agarose, incubated for 4 days, and stained with crystal violets. <b>(B)</b> ECE treatment decreases plaque formation in a dose-dependent manner. …”
    Save to List
    Saved in:
  7. 7
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group.

    After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Patient demographic information at four time points.

    Patient demographic information at four time points. by Ruitian Song (11045127)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: